Patients Discontinuing Weight-Loss Injections Regain Pounds Four Times Faster Than Dieters

Fresh analysis indicates that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who halt traditional lifestyle regimens.

Findings released in a major health publication points out that while obese individuals often shed substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.

"People purchasing such drugs need to be aware of the danger of quick weight regain when the therapy ends," stated researcher Dr. Susan Jebb.

This pace of recovery suggests a reversion to starting weight within about 18 months.

Weighing Approaches

The analysis, which reviewed dozens of trials involving thousands of patients, compared the outcomes of these new drugs with other pills.

Researchers note that people who shed pounds through diet and exercise typically see a more gradual weight regain—approximately 0.1 kg a month—post-intervention.

Understanding the Quick Rebound

Doctors suggest the mechanism of the drugs accounts for the accelerated weight return.

The injections mimic a natural hormone called GLP-1, which moderates hunger.

"Long-term administration of the hormone levels several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.

"Discontinuation of this medication means appetite is no longer kept in check, making overeating a significant risk."

A Chronic Condition?

Medical guidelines advise the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.

A number of clinicians argue that, due to the high risk of weight regain, the therapy should be considered ongoing.

This view is echoed by drug manufacturers, who state that the findings "emphasize the chronic nature of obesity," akin to managing conditions like high blood pressure.

Patient Experiences

Individuals who have stopped the jabs report a sudden return of appetite.

"It felt as if something that goes on and you're instantly extremely hungry," recalled one woman.

This challenge is exacerbated if patients have not developed lasting lifestyle or habit modifications during treatment.

Significant Interest

Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.

• Adoption is higher among females than men.
• The middle-aged demographic shows the greatest level of interest.
• Many access the medications through private healthcare rather than public health services.

Ultimately, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and lasting health benefits likely depends on ongoing lifestyle support.